<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01870401</url>
  </required_header>
  <id_info>
    <org_study_id>CL0005-01</org_study_id>
    <nct_id>NCT01870401</nct_id>
  </id_info>
  <brief_title>Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries</brief_title>
  <official_title>A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Drug Coated Balloon Versus Standard Balloon Angioplasty for Treatment of Below-the-Knee (BTK) Arteries(Lutonix BTK Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bard Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of the Lutonix Drug Coated Balloon (DCB) for treatment of&#xD;
      stenosis or occlusion of native below-the-knee arteries.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 3, 2013</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">May 17, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Freedom From Below-the-Knee (BTK) Major Adverse Limb Event and Peri-Operative Death (POD) at 30 Days Post Index Procedure.</measure>
    <time_frame>30 days post index procedure</time_frame>
    <description>The primary safety endpoint is defined as freedom from the composite of all-cause death, above-ankle amputation or major reintervention (new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis) of the index limb involving a below-the-knee artery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Freedom From the Composite of Above-ankle Amputation, Target Lesion Occlusion, and Clinically-driven Target Lesion Revascularization at 6 Months Post Index Procedure.</measure>
    <time_frame>6 months post-index procedure</time_frame>
    <description>The primary efficacy endpoint is defined as freedom from the composite of above-ankle amputation, target lesion occlusion, and clinically-driven target lesion revascularization. All amputations included in endpoints refer to amputations in the index limb.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Lesions Considered Technical Success at Time of Index Procedure</measure>
    <time_frame>At time of index procedure</time_frame>
    <description>Technical Success: A success is determined if the device success was achieved and a final residual stenosis post study device (DCB or placebo) dilatation ≤ 30% was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Procedures With Procedural Success at Time of Index Procedure.</measure>
    <time_frame>At time of Index Procedure</time_frame>
    <description>A success is determined if there is restoration of at least 1 infrapopliteal artery with residual stenosis ≤ 30% (or ≤ 50% depending upon the version of the protocol) and inline outflow to the foot, irrespective of device success, and without a major adverse event during the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Below the Knee (BTK) Major Adverse Limb Event (MALE) and Perioperative Death (POD) Rate to a Performance Goal at 30 Days Post Index Procedure.</measure>
    <time_frame>30 days post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in European Quality of Life 5 Dimensions (EuroQol -5D) Scores at 30 Days, 6 and 12 Months Compared to Baseline.</measure>
    <time_frame>30 days, 6 and 12 months post index procedure compared to baseline</time_frame>
    <description>Mean change in EuroQol (EQ-5D) scores at 30 days, 6, and 12 months compared to baseline. The EurolQol-5D system rates quality of life using five dimensions including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels of ratings, that is, no problems, slight problems, moderate problems, severe problems and extreme problems that can be selected. A visual scale allows participants to report their own perception of their health status. The overall scores range from 0 (worst) to 100 (best). Please note that the data in the table below represent the mean changes in overall scores for each group compared to their baseline data. Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Lumen Loss at 12 Months Post Index Procedure</measure>
    <time_frame>12 months post-index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Healed Wounds at 30 Days, 6 and 12 Months Post Index Procedure</measure>
    <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
    <description>Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available. The number of wounds analyzed at 6 and 12 months post-index procedure includes wounds that may have appeared (new wounds) since the previous time period reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Non-Healed Wounds by Category (Improving, Stagnant and Worsening) at 30 Days, 6 and 12 Months Post-Index Procedure.</measure>
    <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Existing, New, and Recurrent Wounds at 30 Days, 6 and 12 Months Post Index Procedure.</measure>
    <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
    <description>Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rutherford Classification Scores at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline.</measure>
    <time_frame>30 days, 6 and 12 months post index procedure compared to baseline</time_frame>
    <description>The endpoint summarizes the change in index-limb Rutherford Classification of participants from baseline through 36 months. Data is presented as shift from baseline Rutherford Classification data using the following categories: 1) Improvement, 2) Same, and 3) Worsened.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Above Ankle Amputation, Unhealed Wound, Ischemic Rest Pain, Target Vessel Occlusion, and Clinically-Driven Target Vessel Revascularization (TVR) at 30 Days, 6 and 12 Months Post Index Procedure.</measure>
    <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
    <description>The composite endpoint of freedom from above ankle amputation (CEC-adjudicated), unhealed wound (presence of wound vs. no wound), ischemic rest pain (Rutherford category 4 or higher), target vessel occlusion (based on DUS and/or angiograph), and clinically-driven TVR (CEC-adjudicated).&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Primary Patency Failure at 30 Days, 6 and 12 Months Post Index Procedure</measure>
    <time_frame>30 days and at 6 and 12 months</time_frame>
    <description>Primary patency is defined as the absence of both total occlusion (100% diameter stenosis) in all of the target lesions in a flow pathway as well as a clinically-driven Target Lesion Revascularization (TLR).&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Lesions With Primary Patency Excluding Early Mechanical Recoil at 30 Days, 6 and 12 Months Post Index Procedure</measure>
    <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
    <description>Primary patency with exclusion of early mechanical recoil of the target flow pathway is defined as the absence of both total occlusion (100% diameter stenosis) of the target lesions and clinically-driven TLR events &gt; 30 days.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Lesions With Secondary Patency at 30 Days, 6 and 12 Months Post Index Procedure</measure>
    <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
    <description>The secondary patency of the target lesion is defined as the absence of total occlusion (100% diameter stenosis) of the target lesions based on angiography (if performed) or ultrasound as analyzed by the angiographic Core Lab.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Freedom From Clinically -Driven Target Lesion Revascularization (TLR) and From 50% DS by Angiography or Duplex Ultrasound at 30 Days, 6 and 12 Months Post Index Procedure.</measure>
    <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Toe Brachial Index (TBI) at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline</measure>
    <time_frame>30 days, 6 and 12 months post index procedure compared to baseline</time_frame>
    <description>Mean change from baseline values. The Toe Brachial Index (TBI) is defined as a ratio of toe to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle Brachial Index (ABI) at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline</measure>
    <time_frame>30 days, and at 6 and 12 months compared to baseline</time_frame>
    <description>Mean change from baseline values. The Ankle Brachial Index (ABI) is defined as a ratio of ankle to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Walking Impairment Questionnaire (WIQ) Scores at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline.</measure>
    <time_frame>30 days, 6 and 12 months post index procedure compared to baseline</time_frame>
    <description>The WIQ assesses 3 categories of activities that include 1) walking distance, 2) stair-climbing, and 3) walking speed. Each question requires participants to rate their degree of difficulty with the activity on a scale of 0 (unable) to 4 (no problem). Final scores range from 0% to 100%, with lower percentages indicating higher levels of difficulties with activities.The results below represent the mean differences in total Walking Impairment Questionnaire (WIQ) scores at 30 days 6 and 12 months, compared to baseline assessment scores.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically-Driven Target Lesion Revascularization (TLR) at 30 Days, 6 and 12 Months Post Index Procedure</measure>
    <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Number of Target Lesion Revascularization (TLR) at 30 Days, 6 and 12 Months Post Index Procedure.</measure>
    <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
    <description>Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically-Driven Target Vessel Revascularization (TVR) at 30 Days, 6 and 12 Months Post Index Procedure.</measure>
    <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Number of Target Vessel Revascularization (TVR) at 30 Days, 6 and 12 Months Post Index Procedure.</measure>
    <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Limb Amputation at 30 Days, 6 and 12 Months Post Index Procedure</measure>
    <time_frame>30 days and at 6 and 12 months</time_frame>
    <description>Limb salvage defined as no amputation of target limb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Unplanned Below the Knee (BTK) Amputation of the Target Limb at 30 Days, 6 and 12 Months Post Index Procedure.</measure>
    <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
    <description>Defined as amputation that was below the ankle, including digit amputation. Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Number of of Below the Knee (BTK) Index-Limb Reinterventions at 30 Days, 6 and 12 Months Post Index Procedure.</measure>
    <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
    <description>The overall burden of BTK reinterventions was defined as the total number of BTK index-limb re-interventions and major amputations for each time point.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Composite of Perioperative Death (POD), Index Limb-related Death, Below the Knee Reinterventions or Major Amputations of the Index Limb at 30 Days, 6 and 12 Months Post Index Procedure</measure>
    <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
    <description>Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">442</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Lutonix DCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lutonix Paclitaxel Drug Coated Balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTA Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Uncoated PTA Catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lutonix DCB</intervention_name>
    <arm_group_label>Lutonix DCB</arm_group_label>
    <other_name>LTX DCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Uncoated PTA Catheter</intervention_name>
    <arm_group_label>PTA Catheter</arm_group_label>
    <other_name>PTA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant female ≥18 years of age;&#xD;
&#xD;
          -  Rutherford Clinical Category 3, 4 &amp; 5;&#xD;
&#xD;
          -  Life expectancy ≥ 1 year;&#xD;
&#xD;
          -  Significant stenosis (≥70%)&#xD;
&#xD;
          -  A patent inflow artery;&#xD;
&#xD;
          -  Target vessel(s) diameter between 2 and 4 mm;&#xD;
&#xD;
          -  Target vessel(s) reconstitute(s) at or above the ankle&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or planning on becoming pregnant;&#xD;
&#xD;
          -  History of stroke within 3 months;&#xD;
&#xD;
          -  History of MI, thrombolysis or angina within 30 days of enrollment;&#xD;
&#xD;
          -  Planned major amputation (of either leg)&#xD;
&#xD;
          -  Prior major amputation if amputation occurred less than one year prior to enrollment&#xD;
             and if patient is not independently ambulating;&#xD;
&#xD;
          -  GFR ≤ 30 ml/min per 1.73m2;&#xD;
&#xD;
          -  Acute limb ischemia;&#xD;
&#xD;
          -  In-stent restenosis of target lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Geraghty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jihad Mustapha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metro Health Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne Brodmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Graz, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University-Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Solutions Institute, LLC</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Mease Health Care, Inc</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research of North Florida, LLC</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiology and Imaging Specialists of Lakeland, P.A</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Iowa Hospital Corporation</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIS Clinical Research Corporation</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steward St. Elizabeth Medical Center of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Health-University of Michigan Health Hospital</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Heart Clinic, P.A.</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deborah Heart &amp; Lung Ctr</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Heart Institute, LLC</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NC Heart &amp; Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trihealth Heart Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Corporation</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214-3907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health &amp; Service - Oregon</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital - A Lifespan Partner</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Surgical Associates, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont Cardiology Services, Inc.</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart PLLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Medical Group</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Area Medical Center Health System</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora St. Luke's Vascular Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZOL St. Jan</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Kardiologie • Klinikum Arnsberg GmbH</name>
      <address>
        <city>Arnsberg</city>
        <zip>59759</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets Herzzentrum Freiburg/Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Universitaet Heidelberg,Herzzentrum (Abteilung Innere Medizin III)</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Kempten</name>
      <address>
        <city>Immenstadt</city>
        <zip>87509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig Medical Centre</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Innere Medizin C</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medinos Kliniken des Landkriess Sonneberg GmbH</name>
      <address>
        <city>Sonneberg</city>
        <zip>96515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tubingen, Dept. of Diagnostic and Interventional Radiology</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Cecilia Hospital</name>
      <address>
        <city>Cotignola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasukabe Chuo General Hospital</name>
      <address>
        <city>Kasukabe</city>
        <zip>344-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jikei University Hospital</name>
      <address>
        <city>Minato-ku, Tokyo</city>
        <zip>105-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morinomiya Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>536-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kishiwada Tokushukai Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>596-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University</name>
      <address>
        <city>Tokyo</city>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 7, 2013</study_first_submitted>
  <study_first_submitted_qc>June 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <results_first_submitted>May 26, 2020</results_first_submitted>
  <results_first_submitted_qc>August 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2020</results_first_posted>
  <disposition_first_submitted>July 23, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>July 31, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 8, 2019</disposition_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT01870401/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from medical clinics and hospitals between June 2013 and January 2018. The first participant was enrolled on June 3, 2013 and the last participant enrolled was on December 12, 2017.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lutonix DCB</title>
          <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
        </group>
        <group group_id="P2">
          <title>Standard Balloon Angioplasty Catheter</title>
          <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>On-going in the Study</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lutonix DCB</title>
          <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
        </group>
        <group group_id="B2">
          <title>Standard Balloon Angioplasty Catheter</title>
          <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="287"/>
            <count group_id="B2" value="155"/>
            <count group_id="B3" value="442"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.9" spread="9.65"/>
                    <measurement group_id="B2" value="72.9" spread="9.62"/>
                    <measurement group_id="B3" value="72.9" spread="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.6" spread="21.15"/>
                    <measurement group_id="B2" value="81.9" spread="20.29"/>
                    <measurement group_id="B3" value="82.3" spread="20.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170" spread="10.07"/>
                    <measurement group_id="B2" value="170" spread="10.65"/>
                    <measurement group_id="B3" value="170" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.4" spread="6.31"/>
                    <measurement group_id="B2" value="28.0" spread="5.65"/>
                    <measurement group_id="B3" value="28.2" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Freedom From Below-the-Knee (BTK) Major Adverse Limb Event and Peri-Operative Death (POD) at 30 Days Post Index Procedure.</title>
        <description>The primary safety endpoint is defined as freedom from the composite of all-cause death, above-ankle amputation or major reintervention (new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis) of the index limb involving a below-the-knee artery.</description>
        <time_frame>30 days post index procedure</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Lutonix Paclitaxel Drug Coated Balloon&#xD;
Lutonix DCB</description>
          </group>
          <group group_id="O2">
            <title>PTA Catheter</title>
            <description>Standard Uncoated PTA Catheter&#xD;
Uncoated PTA Catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Below-the-Knee (BTK) Major Adverse Limb Event and Peri-Operative Death (POD) at 30 Days Post Index Procedure.</title>
          <description>The primary safety endpoint is defined as freedom from the composite of all-cause death, above-ankle amputation or major reintervention (new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis) of the index limb involving a below-the-knee artery.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary safety hypothesis is as follows: H0: pControl - pDCB ≥ and H1: pControl (alpha) pDCB &lt; where p is the success rate in each arm and (alpha) is the non-inferiority bound.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The protocol identified a non-inferiority bound equal to 0.12 (12%).</non_inferiority_desc>
            <p_value>&lt;0.025</p_value>
            <method>Farrington and Manning</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Freedom From the Composite of Above-ankle Amputation, Target Lesion Occlusion, and Clinically-driven Target Lesion Revascularization at 6 Months Post Index Procedure.</title>
        <description>The primary efficacy endpoint is defined as freedom from the composite of above-ankle amputation, target lesion occlusion, and clinically-driven target lesion revascularization. All amputations included in endpoints refer to amputations in the index limb.</description>
        <time_frame>6 months post-index procedure</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From the Composite of Above-ankle Amputation, Target Lesion Occlusion, and Clinically-driven Target Lesion Revascularization at 6 Months Post Index Procedure.</title>
          <description>The primary efficacy endpoint is defined as freedom from the composite of above-ankle amputation, target lesion occlusion, and clinically-driven target lesion revascularization. All amputations included in endpoints refer to amputations in the index limb.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0222</p_value>
            <method>Wald Test</method>
            <method_desc>One-sided Wald test based on model estimate of DCB treatment effect and subject as a random effect.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Lesions Considered Technical Success at Time of Index Procedure</title>
        <description>Technical Success: A success is determined if the device success was achieved and a final residual stenosis post study device (DCB or placebo) dilatation ≤ 30% was reported.</description>
        <time_frame>At time of index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Lesions Considered Technical Success at Time of Index Procedure</title>
          <description>Technical Success: A success is determined if the device success was achieved and a final residual stenosis post study device (DCB or placebo) dilatation ≤ 30% was reported.</description>
          <units>percentage of lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3" lower_limit="51.4" upper_limit="70.6"/>
                    <measurement group_id="O2" value="58.3" lower_limit="44.9" upper_limit="70.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Procedures With Procedural Success at Time of Index Procedure.</title>
        <description>A success is determined if there is restoration of at least 1 infrapopliteal artery with residual stenosis ≤ 30% (or ≤ 50% depending upon the version of the protocol) and inline outflow to the foot, irrespective of device success, and without a major adverse event during the index procedure.</description>
        <time_frame>At time of Index Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Procedures With Procedural Success at Time of Index Procedure.</title>
          <description>A success is determined if there is restoration of at least 1 infrapopliteal artery with residual stenosis ≤ 30% (or ≤ 50% depending upon the version of the protocol) and inline outflow to the foot, irrespective of device success, and without a major adverse event during the index procedure.</description>
          <units>Percentage of Procedures</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0" lower_limit="79.5" upper_limit="87.9"/>
                    <measurement group_id="O2" value="81.4" lower_limit="74.8" upper_limit="86.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of the Below the Knee (BTK) Major Adverse Limb Event (MALE) and Perioperative Death (POD) Rate to a Performance Goal at 30 Days Post Index Procedure.</title>
        <time_frame>30 days post index procedure</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Below the Knee (BTK) Major Adverse Limb Event (MALE) and Perioperative Death (POD) Rate to a Performance Goal at 30 Days Post Index Procedure.</title>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in European Quality of Life 5 Dimensions (EuroQol -5D) Scores at 30 Days, 6 and 12 Months Compared to Baseline.</title>
        <description>Mean change in EuroQol (EQ-5D) scores at 30 days, 6, and 12 months compared to baseline. The EurolQol-5D system rates quality of life using five dimensions including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels of ratings, that is, no problems, slight problems, moderate problems, severe problems and extreme problems that can be selected. A visual scale allows participants to report their own perception of their health status. The overall scores range from 0 (worst) to 100 (best). Please note that the data in the table below represent the mean changes in overall scores for each group compared to their baseline data. Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
        <time_frame>30 days, 6 and 12 months post index procedure compared to baseline</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in European Quality of Life 5 Dimensions (EuroQol -5D) Scores at 30 Days, 6 and 12 Months Compared to Baseline.</title>
          <description>Mean change in EuroQol (EQ-5D) scores at 30 days, 6, and 12 months compared to baseline. The EurolQol-5D system rates quality of life using five dimensions including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels of ratings, that is, no problems, slight problems, moderate problems, severe problems and extreme problems that can be selected. A visual scale allows participants to report their own perception of their health status. The overall scores range from 0 (worst) to 100 (best). Please note that the data in the table below represent the mean changes in overall scores for each group compared to their baseline data. Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="0.458"/>
                    <measurement group_id="O2" value="0.53" spread="0.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="245"/>
                    <count group_id="O2" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.300"/>
                    <measurement group_id="O2" value="0.05" spread="0.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="227"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.284"/>
                    <measurement group_id="O2" value="0.12" spread="0.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Lumen Loss at 12 Months Post Index Procedure</title>
        <time_frame>12 months post-index procedure</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Late Lumen Loss at 12 Months Post Index Procedure</title>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Healed Wounds at 30 Days, 6 and 12 Months Post Index Procedure</title>
        <description>Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available. The number of wounds analyzed at 6 and 12 months post-index procedure includes wounds that may have appeared (new wounds) since the previous time period reporting.</description>
        <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Healed Wounds at 30 Days, 6 and 12 Months Post Index Procedure</title>
          <description>Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available. The number of wounds analyzed at 6 and 12 months post-index procedure includes wounds that may have appeared (new wounds) since the previous time period reporting.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Wounds</units>
          <param>Count of Units</param>
          <units_analyzed>Wounds</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Wounds</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="143"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Wounds</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="122"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Wounds</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="108"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Wounds</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Non-Healed Wounds by Category (Improving, Stagnant and Worsening) at 30 Days, 6 and 12 Months Post-Index Procedure.</title>
        <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Non-Healed Wounds by Category (Improving, Stagnant and Worsening) at 30 Days, 6 and 12 Months Post-Index Procedure.</title>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Non-Healed Wounds</units>
          <param>Count of Units</param>
          <units_analyzed>Non-Healed Wounds</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Non-Healed Wounds</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Non-Healed Wounds</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improving</title>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stagnant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Non-Healed Wounds</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improving</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stagnant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Non-Healed Wounds</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improving</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stagnant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsening</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Existing, New, and Recurrent Wounds at 30 Days, 6 and 12 Months Post Index Procedure.</title>
        <description>Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
        <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
        <population>Participants may have more than one wound type or wounds in more than one location. The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Existing, New, and Recurrent Wounds at 30 Days, 6 and 12 Months Post Index Procedure.</title>
          <description>Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
          <population>Participants may have more than one wound type or wounds in more than one location. The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Wounds</units>
          <param>Count of Units</param>
          <units_analyzed>Wounds</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Wounds</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="97"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Wounds</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Existing Wounds</title>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>New Wounds</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Recurrent Wounds</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="97"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Wounds</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Existing Wounds</title>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>New Wounds</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Recurrent Wounds</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="97"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Wounds</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Existing Wounds</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>New Wounds</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Recurrent Wounds</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Rutherford Classification Scores at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline.</title>
        <description>The endpoint summarizes the change in index-limb Rutherford Classification of participants from baseline through 36 months. Data is presented as shift from baseline Rutherford Classification data using the following categories: 1) Improvement, 2) Same, and 3) Worsened.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
        <time_frame>30 days, 6 and 12 months post index procedure compared to baseline</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Rutherford Classification Scores at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline.</title>
          <description>The endpoint summarizes the change in index-limb Rutherford Classification of participants from baseline through 36 months. Data is presented as shift from baseline Rutherford Classification data using the following categories: 1) Improvement, 2) Same, and 3) Worsened.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="263"/>
                    <count group_id="O2" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Above Ankle Amputation, Unhealed Wound, Ischemic Rest Pain, Target Vessel Occlusion, and Clinically-Driven Target Vessel Revascularization (TVR) at 30 Days, 6 and 12 Months Post Index Procedure.</title>
        <description>The composite endpoint of freedom from above ankle amputation (CEC-adjudicated), unhealed wound (presence of wound vs. no wound), ischemic rest pain (Rutherford category 4 or higher), target vessel occlusion (based on DUS and/or angiograph), and clinically-driven TVR (CEC-adjudicated).&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
        <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Above Ankle Amputation, Unhealed Wound, Ischemic Rest Pain, Target Vessel Occlusion, and Clinically-Driven Target Vessel Revascularization (TVR) at 30 Days, 6 and 12 Months Post Index Procedure.</title>
          <description>The composite endpoint of freedom from above ankle amputation (CEC-adjudicated), unhealed wound (presence of wound vs. no wound), ischemic rest pain (Rutherford category 4 or higher), target vessel occlusion (based on DUS and/or angiograph), and clinically-driven TVR (CEC-adjudicated).&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="263"/>
                    <count group_id="O2" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="241"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Primary Patency Failure at 30 Days, 6 and 12 Months Post Index Procedure</title>
        <description>Primary patency is defined as the absence of both total occlusion (100% diameter stenosis) in all of the target lesions in a flow pathway as well as a clinically-driven Target Lesion Revascularization (TLR).&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
        <time_frame>30 days and at 6 and 12 months</time_frame>
        <population>The number of participants or lesions may vary depending on the number of participants/lesions for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Primary Patency Failure at 30 Days, 6 and 12 Months Post Index Procedure</title>
          <description>Primary patency is defined as the absence of both total occlusion (100% diameter stenosis) in all of the target lesions in a flow pathway as well as a clinically-driven Target Lesion Revascularization (TLR).&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
          <population>The number of participants or lesions may vary depending on the number of participants/lesions for which data was available at the given time-point analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="261"/>
                    <count group_id="O2" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="94.6" upper_limit="98.7"/>
                    <measurement group_id="O2" value="94.8" lower_limit="89.4" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" lower_limit="80.2" upper_limit="89.1"/>
                    <measurement group_id="O2" value="72.2" lower_limit="63.3" upper_limit="79.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1" lower_limit="51.5" upper_limit="64.2"/>
                    <measurement group_id="O2" value="60.0" lower_limit="50.6" upper_limit="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Lesions With Primary Patency Excluding Early Mechanical Recoil at 30 Days, 6 and 12 Months Post Index Procedure</title>
        <description>Primary patency with exclusion of early mechanical recoil of the target flow pathway is defined as the absence of both total occlusion (100% diameter stenosis) of the target lesions and clinically-driven TLR events &gt; 30 days.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
        <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
        <population>The number of participants or lesions may vary depending on the number of participants/lesions for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Lesions With Primary Patency Excluding Early Mechanical Recoil at 30 Days, 6 and 12 Months Post Index Procedure</title>
          <description>Primary patency with exclusion of early mechanical recoil of the target flow pathway is defined as the absence of both total occlusion (100% diameter stenosis) of the target lesions and clinically-driven TLR events &gt; 30 days.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
          <population>The number of participants or lesions may vary depending on the number of participants/lesions for which data was available at the given time-point analysis.</population>
          <units>Percentage of Lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Lesions</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Lesions</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0" lower_limit="83.5" upper_limit="91.3"/>
                    <measurement group_id="O2" value="73.8" lower_limit="65.5" upper_limit="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Lesions</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="151"/>
                    <count group_id="O2" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" lower_limit="55.4" upper_limit="67.3"/>
                    <measurement group_id="O2" value="63.0" lower_limit="54.2" upper_limit="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Lesions With Secondary Patency at 30 Days, 6 and 12 Months Post Index Procedure</title>
        <description>The secondary patency of the target lesion is defined as the absence of total occlusion (100% diameter stenosis) of the target lesions based on angiography (if performed) or ultrasound as analyzed by the angiographic Core Lab.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
        <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lesions With Secondary Patency at 30 Days, 6 and 12 Months Post Index Procedure</title>
          <description>The secondary patency of the target lesion is defined as the absence of total occlusion (100% diameter stenosis) of the target lesions based on angiography (if performed) or ultrasound as analyzed by the angiographic Core Lab.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis</population>
          <units>Lesions</units>
          <param>Number</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Lesions</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Lesions</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
                <analyzed>
                  <units>Lesions</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of Freedom From Clinically -Driven Target Lesion Revascularization (TLR) and From 50% DS by Angiography or Duplex Ultrasound at 30 Days, 6 and 12 Months Post Index Procedure.</title>
        <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Freedom From Clinically -Driven Target Lesion Revascularization (TLR) and From 50% DS by Angiography or Duplex Ultrasound at 30 Days, 6 and 12 Months Post Index Procedure.</title>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Toe Brachial Index (TBI) at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline</title>
        <description>Mean change from baseline values. The Toe Brachial Index (TBI) is defined as a ratio of toe to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
        <time_frame>30 days, 6 and 12 months post index procedure compared to baseline</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Toe Brachial Index (TBI) at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline</title>
          <description>Mean change from baseline values. The Toe Brachial Index (TBI) is defined as a ratio of toe to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.25"/>
                    <measurement group_id="O2" value="0.28" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.24"/>
                    <measurement group_id="O2" value="0.17" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.23"/>
                    <measurement group_id="O2" value="0.18" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ankle Brachial Index (ABI) at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline</title>
        <description>Mean change from baseline values. The Ankle Brachial Index (ABI) is defined as a ratio of ankle to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
        <time_frame>30 days, and at 6 and 12 months compared to baseline</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle Brachial Index (ABI) at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline</title>
          <description>Mean change from baseline values. The Ankle Brachial Index (ABI) is defined as a ratio of ankle to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="128"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.36"/>
                    <measurement group_id="O2" value="0.28" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="218"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.36"/>
                    <measurement group_id="O2" value="0.17" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.36"/>
                    <measurement group_id="O2" value="0.18" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Walking Impairment Questionnaire (WIQ) Scores at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline.</title>
        <description>The WIQ assesses 3 categories of activities that include 1) walking distance, 2) stair-climbing, and 3) walking speed. Each question requires participants to rate their degree of difficulty with the activity on a scale of 0 (unable) to 4 (no problem). Final scores range from 0% to 100%, with lower percentages indicating higher levels of difficulties with activities.The results below represent the mean differences in total Walking Impairment Questionnaire (WIQ) scores at 30 days 6 and 12 months, compared to baseline assessment scores.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
        <time_frame>30 days, 6 and 12 months post index procedure compared to baseline</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Walking Impairment Questionnaire (WIQ) Scores at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline.</title>
          <description>The WIQ assesses 3 categories of activities that include 1) walking distance, 2) stair-climbing, and 3) walking speed. Each question requires participants to rate their degree of difficulty with the activity on a scale of 0 (unable) to 4 (no problem). Final scores range from 0% to 100%, with lower percentages indicating higher levels of difficulties with activities.The results below represent the mean differences in total Walking Impairment Questionnaire (WIQ) scores at 30 days 6 and 12 months, compared to baseline assessment scores.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="18.13"/>
                    <measurement group_id="O2" value="1.1" spread="17.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="238"/>
                    <count group_id="O2" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="21.55"/>
                    <measurement group_id="O2" value="3.6" spread="20.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="218"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="22.10"/>
                    <measurement group_id="O2" value="2.3" spread="20.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically-Driven Target Lesion Revascularization (TLR) at 30 Days, 6 and 12 Months Post Index Procedure</title>
        <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically-Driven Target Lesion Revascularization (TLR) at 30 Days, 6 and 12 Months Post Index Procedure</title>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Number of Target Lesion Revascularization (TLR) at 30 Days, 6 and 12 Months Post Index Procedure.</title>
        <description>Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
        <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of Target Lesion Revascularization (TLR) at 30 Days, 6 and 12 Months Post Index Procedure.</title>
          <description>Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Target Lesions Revascularization</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target Lesions Revascularization</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically-Driven Target Vessel Revascularization (TVR) at 30 Days, 6 and 12 Months Post Index Procedure.</title>
        <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically-Driven Target Vessel Revascularization (TVR) at 30 Days, 6 and 12 Months Post Index Procedure.</title>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Number of Target Vessel Revascularization (TVR) at 30 Days, 6 and 12 Months Post Index Procedure.</title>
        <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of Target Vessel Revascularization (TVR) at 30 Days, 6 and 12 Months Post Index Procedure.</title>
          <units>Target Vessel Revascualarization</units>
          <param>Number</param>
          <units_analyzed>Target Vessel Revascularization</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target Vessel Revascularization</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Limb Amputation at 30 Days, 6 and 12 Months Post Index Procedure</title>
        <description>Limb salvage defined as no amputation of target limb.</description>
        <time_frame>30 days and at 6 and 12 months</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Limb Amputation at 30 Days, 6 and 12 Months Post Index Procedure</title>
          <description>Limb salvage defined as no amputation of target limb.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96.6" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.0" lower_limit="93.9" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="241"/>
                    <count group_id="O2" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="94.5" upper_limit="98.7"/>
                    <measurement group_id="O2" value="98.0" lower_limit="93.9" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Unplanned Below the Knee (BTK) Amputation of the Target Limb at 30 Days, 6 and 12 Months Post Index Procedure.</title>
        <description>Defined as amputation that was below the ankle, including digit amputation. Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
        <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Unplanned Below the Knee (BTK) Amputation of the Target Limb at 30 Days, 6 and 12 Months Post Index Procedure.</title>
          <description>Defined as amputation that was below the ankle, including digit amputation. Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" lower_limit="92.7" upper_limit="97.6"/>
                    <measurement group_id="O2" value="95.5" lower_limit="90.8" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="242"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6" lower_limit="84.2" upper_limit="91.8"/>
                    <measurement group_id="O2" value="88.2" lower_limit="81.9" upper_limit="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3" lower_limit="81.6" upper_limit="89.8"/>
                    <measurement group_id="O2" value="83.1" lower_limit="76.0" upper_limit="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Number of of Below the Knee (BTK) Index-Limb Reinterventions at 30 Days, 6 and 12 Months Post Index Procedure.</title>
        <description>The overall burden of BTK reinterventions was defined as the total number of BTK index-limb re-interventions and major amputations for each time point.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
        <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of of Below the Knee (BTK) Index-Limb Reinterventions at 30 Days, 6 and 12 Months Post Index Procedure.</title>
          <description>The overall burden of BTK reinterventions was defined as the total number of BTK index-limb re-interventions and major amputations for each time point.&#xD;
Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
          <units>Limb Reintervention</units>
          <param>Number</param>
          <units_analyzed>Limb Reintervention</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Limb Reintervention</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="365"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Composite of Perioperative Death (POD), Index Limb-related Death, Below the Knee Reinterventions or Major Amputations of the Index Limb at 30 Days, 6 and 12 Months Post Index Procedure</title>
        <description>Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
        <time_frame>30 days, 6 and 12 months post index procedure</time_frame>
        <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lutonix DCB</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
          <group group_id="O2">
            <title>Standard Balloon Angioplasty Catheter</title>
            <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Composite of Perioperative Death (POD), Index Limb-related Death, Below the Knee Reinterventions or Major Amputations of the Index Limb at 30 Days, 6 and 12 Months Post Index Procedure</title>
          <description>Results for 24 and 36 months will be reported when the final Clinical Study Report becomes available.</description>
          <population>The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-days Post Index Procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" lower_limit="89.8" upper_limit="95.7"/>
                    <measurement group_id="O2" value="90.3" lower_limit="84.5" upper_limit="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" lower_limit="73.6" upper_limit="83.2"/>
                    <measurement group_id="O2" value="69.6" lower_limit="61.6" upper_limit="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post index procedure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" lower_limit="50.6" upper_limit="62.5"/>
                    <measurement group_id="O2" value="58.0" lower_limit="49.5" upper_limit="65.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects with Serious Adverse Events by Body System and Preferred Term are presented through 36 Months and are Site-reported. All devices and procedure-related adverse events (AEs) were collected through 36 months post index procedure and are CEC adjudicated.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lutonix DCB</title>
          <description>Percutaneous transluminal angiography (PTA) will be performed using the Lutonix Drug Coated Balloon.&#xD;
Lutonix DCB&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
        </group>
        <group group_id="E2">
          <title>Standard Balloon Angioplasty Catheter</title>
          <description>Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.&#xD;
Standard Balloon Angioplasty Catheter&#xD;
Percutaneous Transluminal Angiography: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a &quot;balloon&quot; at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="240" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Anaemia Of Chronic Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Heparin-Induced Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypochromic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nephrogenic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Aortic Valve Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Aortic Valve Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Arrhythmia Supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrial Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Left</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ischaemic Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Left Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pulseless Electrical Activity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Right Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tricuspid Valve Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tricuspid Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ventricular Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Buried Penis Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle Closure Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diabetic Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Eye Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Abdominal Wall Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Colitis Ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dental Caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Faecal Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ileus Paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia, Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Intestinal Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Intestinal Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ischaemic Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Large Intestine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Mesenteric Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Oesophagitis Ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Drug Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Device Battery Issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Device Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Device Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Impaired Healing</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Local Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Systemic Inflammatory Response Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Acute Ischemia Left Lower Leg</sub_title>
                <description>This SAE was uncoded in terms of Organ System in the Clinical Study Report and therefore, is added here under &quot;General Disorders&quot;.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Admission to Psychiatry</sub_title>
                <description>This SAE was uncoded in terms of Organ System in the Clinical Study Report and therefore, is added here under &quot;General Disorders&quot;.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Chest Pain Syndrome with Acute Moderate Pericardia</sub_title>
                <description>This SAE was uncoded in terms of Organ System in the Clinical Study Report and therefore, is added here under &quot;General Disorders&quot;.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Claudication Left Leg</sub_title>
                <description>This SAE was uncoded in terms of Organ System in the Clinical Study Report and therefore, is added here under &quot;General Disorders&quot;.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gangrene on Left Great Toe</sub_title>
                <description>This SAE was uncoded in terms of Organ System in the Clinical Study Report and therefore, is added here under &quot;General Disorders&quot;.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>I &amp; D with Partial Left Hallux Amputation</sub_title>
                <description>This SAE was uncoded in terms of Organ System in the Clinical Study Report and therefore, is added here under &quot;General Disorders&quot;.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Occluded Left Sfa Stent</sub_title>
                <description>This SAE was uncoded in terms of Organ System in the Clinical Study Report and therefore, is added here under &quot;General Disorders&quot;.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Occlusion of Right At &amp; Dp</sub_title>
                <description>This SAE was uncoded in terms of Organ System in the Clinical Study Report and therefore, is added here under &quot;General Disorders&quot;.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Occlusion of Left At and Stenosis of Left Tpt</sub_title>
                <description>This SAE was uncoded in terms of Organ System in the Clinical Study Report and therefore, is added here under &quot;General Disorders&quot;.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Profundus Stenosis</sub_title>
                <description>This SAE was uncoded in terms of Organ System in the Clinical Study Report and therefore, is added here under &quot;General Disorders&quot;.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ulcerated Basalioma Left Eyelid</sub_title>
                <description>This SAE was uncoded in terms of Organ System in the Clinical Study Report and therefore, is added here under &quot;General Disorders&quot;.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atypical Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diabetic Foot Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Emphysematous Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Groin Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Infected Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Intervertebral Discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lung Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Serratia Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sputum Purulent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia Postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Coronary Artery Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Forearm Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Iatrogenic Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lumbar Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Meniscus Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Patella Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Reocclusion</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Post Procedural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Skin Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Subcutaneous Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Thoracic Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Traumatic Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vascular Graft Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vascular Graft Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vascular Graft Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Wound Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Wound Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood Culture Positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood Glucose Fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood Pressure Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Radioisotope Scan Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Troponin Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cervical Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Foot Deformity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Joint Contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Joint Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rotator Cuff Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Soft Tissue Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma Pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Adenosquamous Cell Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Colorectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lip And/Or Oral Cavity Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neuroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Non-Small Cell Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pharyngeal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Renal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma Of Lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Brain Stem Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Embolic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lacunar Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Metabolic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Parkinson's Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Precerebral Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Toxic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vascular Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neglect Of Personal Appearance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nephropathy Toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Obstructive Uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Renal Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ureteric Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pulmonary Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sleep Apnoea Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diabetic Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dry Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Leukocytoclastic Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Skin Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Arterial Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Arteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diabetic Macroangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Embolism Arterial</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Extremity Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Femoral Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypertensive Emergency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Dissection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Varicose Vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vascular Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Venous Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vessel Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Retroperitoneal Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Local Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Puncture Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Stent Malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Worsening of Peripheral Artery Disease</sub_title>
                <description>This SAE was uncoded in terms of Organ System in the Clinical Study Report and therefore, is added here under &quot;General Disorders&quot;.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Peripheral Arterial Reocclusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Incision Site Complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Reocclusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Scrotal Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Subcutaneous Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urine Analysis Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nephropathy Toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism Arterial</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Dissection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Arteriovenous Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Dissection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vessel Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa Erickson</name_or_title>
      <organization>Becton Dickinson</organization>
      <phone>763-463-2897</phone>
      <email>Lisa.Erickson@bd.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

